Thursday, July 16, 2026 - KFF Health News
• Researchers have published a new study in Science Translational Medicine detailing how the Epstein-Barr virus triggers immune responses that cause inflammation and nervous system damage in multiple sclerosis patients. • Separately, clinical trials have demonstrated the effectiveness of a treatment that inhibits the PCSK9 protein to significantly lower dangerous LDL cholesterol levels. • This cholesterol treatment can reduce LDL levels to 50 or 60, whereas adults not using medication typically maintain levels above 100.
kffhealthnews.org